Doxorubicin Loaded DNA Aptamer Linked Myristilated Chitosan Nanogel for Targeted Drug Delivery to Prostate Cancer

Authors

  • Fereshteh Atabi Department of Biology, Science and research branch, Islamic Azad University, Tehran, IRAN
  • Mehrdad Hashemi Associate of prod.,Departmaent of Genetics,IAU,Tehran medical branch
  • Parichehreh Yaghmaei Department of Biology, Science and research branch, Islamic Azad University, Tehran, IRAN
Abstract:

Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded with Doxorubicin (DOX) to be used in targeted drug delivery against the Prostate cancer cells. LNCaP and PC-3 cells were treated with Apt-MCS-DOX complex and the binding efficiency was estimated by flow cytometry. The binding affinity of the selected aptamers was above 70% compared to the initial library. The loading capacity of the nanogel was as high as 97% and up to 40% of DOX were released from MCS within 15 days.Cytotoxicity of nanodrugs on LNCaP cells were determined by MTT assay. Apt-MCS-DOX was specifically binded to LNCaP cells whereas it didn’t show any specificity to PC-3 cells as a negative control. Both MCS-DOX and Apt-MCS-DOX showed a lethal effect on LNCaP cells. Our results can lead to an aptamer based simple and applicable technique for early diagnosis and treatment of cancerous cells.Keywords: DOX; MCS; nanogel; aptamer; Targeted drug delivery; Prostate cancer.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

doxorubicin loaded dna aptamer linked myristilated chitosan nanogel for targeted drug delivery to prostate cancer

recently, specific attention has been paid to aptamers, short dna or rna, as a tool for cancer diagnosis and therapy. in the present study mcs nanogels were prepared by myristate: chitosan at 1:9 ratio and were characterized by several techniques. a selected ssdna aptamer(apt) capable of detecting lncap cells was linked to myristilated chitosan nanogels (apt-mcs) by glutaraldehyde and loaded wi...

full text

A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery

The side effects of radio- and chemo-therapy pose long-term challenges on a cancer patient's health. It is, therefore, highly desirable to develop more effective therapies that can specifically target carcinoma cells without damaging normal and healthy cells. Tremendous efforts have been made in the past to develop targeted drug delivery systems for solid cancer treatment. In this study, a new ...

full text

Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery

This work investigated the preparation of chitosan nanoparticles used as carriers for doxorubicin for targeted cancer delivery. Prepared nanocarriers were stabilized and functionalized via zinc ions incorporated into the chitosan nanoparticle backbone. We took the advantage of high expression of sarcosine in the prostate cancer cells. The prostate cancer targeting was mediated by the AntiSar an...

full text

Aptamer-Targeted DNA Nanostructures for Therapeutic Delivery

DNA-based nanostructures have been widely used in various applications due to their structural diversity, programmability, and uniform structures. Their intrinsic biocompatibility and biodegradability further motivates the investigation of DNA-based nanostructures as delivery vehicles. Incorporating AS1411 aptamers into DNA pyramids leads to enhanced intracellular uptake and selectively inhibit...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 16  issue 1

pages  35- 49

publication date 2017-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023